Skip to main content
Fig. 2 | BMC Nephrology

Fig. 2

From: An open-label phase 2 trial to assess the efficacy, safety and pharmacokinetics of lanthanum carbonate in hyperphosphatemic children and adolescents with chronic kidney disease undergoing dialysis

Fig. 2

CONSORT flow diagram. a Patient was receiving hemodialysis. b Patients were receiving hemodialysis (n = 3) and peritoneal dialysis (n = 2). c Patients were receiving hemodialysis (n = 1) and peritoneal dialysis (n = 2). d Patients were receiving hemodialysis (n = 2) and peritoneal dialysis (n = 1). e Patient was receiving peritoneal dialysis. f Patients were receiving hemodialysis (n = 2) and peritoneal dialysis (n = 4). g One patient who received CC during part 2 proceeded to part 3 to receive LC for up to 6 months

CC calcium carbonate, CONSORT Consolidated Standards of Reporting Trials, LC lanthanum carbonate

Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us